WADA 2026: Testing Growth Slows, and a Compliance Gap Few Notice

For four consecutive years I logged the out-of-competition testing schedules at swimming meets across Asia-Pacific, and I learned something that rarely gets said out loud: sample volumes never rise in a straight line. They surge one year, flatten the next, then creep up a little. The World Anti-Doping Agency's 2026 annual report, released this month, confirms exactly that pattern — just not in the way its headline suggests. In 2026, anti-doping organizations worldwide collected 288,865 samples. In 2026, the figure was 297,965, an increase of roughly 9,100. At first glance, that is a good year. But placed side by side, growth fell from 12.5% (2026 to 2026) to 3.2% (2026 to 2026). The curve is flattening, and for someone who reads data for a living, that detail is decisive — it is the whole story. I still remember mispronouncing a player's name at the 2026 World Cup and being corrected on air. That night I sat for four hours, not to apologize, but to build a systematic reference sheet for every name and every role. The lesson was clear: accuracy must come from systems, not memory. WADA's report works on the same logic. To understand it, you cannot read only the first-page number; you must read the whole series. Before dissecting each data cluster, the report needs to be placed correctly. It is a governance document, not a performance summary. It says nothing about stroke technique, no specific swimmer, no medal. It is about the machinery: who collects samples, who audits whom, who pays, and where the gaps sit. The report splits into four blocks. The first covers global testing data, including total samples and adverse findings. The second covers national anti-doping organizations' compliance, through audits. The third is the financial picture, revenues and expenditures. The fourth is strategic direction, including the shift toward investigations and prevention. One timing point must be clarified upfront. The report carries a 2026 label, but most testing data centers on 2026 and 2026. This labeling is common in international governance bodies: published in 2026, summarizing the prior year's activity with a one-year lag. For a data reader, this matters, because mislabeling the year distorts every time-series comparison. A headline citing "2026 data" when the figures describe 2026 will lead readers to a wrong conclusion about growth momentum. For swimming, the report matters at a different layer than for team sports. Swimming consumes a very high volume of samples, because its competition system is split across many events, distances, and strokes, with international meets spread across the calendar. A country with a developed swimming program must run a year-round out-of-competition testing operation, far more frequent than a sport with only a few major events annually. When the global governance body faces resource problems, small swimming federations feel it first — they lack both infrastructure and a voice in allocation decisions. One more note on the document's nature. WADA sets standards, but enforcement largely sits with national anti-doping organizations and sport federations. This structure creates a long chain of responsibility, where a sampling error in one country can invalidate an entire case while the global report still displays clean numbers. Reading WADA's report by looking only at totals means missing that chain entirely. Start with the testing series. The report presents continuous data from 2026 to 2026 — a rare strength, since the series is long enough to separate trend from noise. As noted, total samples rose from 288,865 to 297,965, roughly 9,100 more, but growth decelerated from 12.5% to 3.2%. Averaged over seven years, the increase remains positive, but the momentum weakens each cycle. More notable is the rate of adverse analytical findings, or AAF — a formal positive test for a prohibited substance or method. Across three consecutive years, the rate was 0.77%, 0.80%, and 0.78%. That is essentially flat, oscillating within a 0.03 percentage-point band. Here a problem of interpretation emerges that most short reports skip. When testing volume rises but detection rates stay flat, there are two entirely different readings. First: doping prevalence is genuinely stable, and expanded testing simply reflects broader coverage. Second: testing has reached a new population with a positivity rate comparable to the old one, leaving the aggregate rate unchanged even as its composition shifts. The data alone cannot separate these. What is concerning is that general readers default to the first reading and ignore the second. Data does not judge, but it points me to the questions others forget. The biggest risk of a flat rate is that it gets read as reassurance. In statistical analysis, a flat rate says nothing about absolute doping prevalence. It says only that, within the tested sample, detection did not change. If testing scope shifts, the rate's meaning shifts too, even when the figure looks identical year over year. The third metric, and in my view the most important, sits in the compliance audit section. National anti-doping organizations are periodically assessed by WADA. Average non-conformities fell from 25.5 to 20 — apparently a clear improvement. But that figure rests on just nine audits in the reported cycle. Nine audits, for the entire global network of countries. With a sample that small, the improvement may be random variation rather than a durable trend. Nine observations cannot establish that a system is getting better. More dangerously, isolating testing-related findings flips the picture entirely. Those findings account for 45% of all findings, up 11% year over year, and 23% of them were classified as critical. In other words, while the aggregate picture looks brighter, the system's most vulnerable component — sample collection and handling — is deteriorating. I call this a hidden deterioration. It never appears in headlines, never in press releases, but sits exactly where it matters most. An audit showing fewer total findings means little if the most serious findings are rising. Some discoveries do not come from luck, but from being willing to read the movements the crowd overlooks. Here, that movement is an 11% figure buried among dozens of others. For swimming, procedural testing errors are the most dangerous kind, because they strike at a case's legal validity. A sample collected under the wrong procedure, a broken chain of custody, an improper notification — any of these can render a result worthless before a hearing, even if biologically the sample was sound. When error rates in this area rise 11%, small federations with few dedicated staff are the most exposed. Turning to finances. WADA recorded a revenue shortfall of $8.3 million against plan. The two largest gaps came from the system's most influential countries: the United States at $3.8 million and Russia at $3.9 million. These account for most of the shortfall, not minor rounding. Notably, the two debts differ in nature. Russia's ties to prolonged political tension between the country and the international sports system, a story accumulating for years. The US gap comes from a country that has been a core WADA funder for decades. When both anchors fall behind, the issue stops being purely financial and becomes one of who really stands behind the enforcement machinery. An agency that writes rules but does not control its own resources will struggle to enforce them. Meanwhile, the report still records a net surplus of $1.2 million. A surplus coexisting with a large shortfall is a telling signal. Accounting-wise, an organization can post both if it cuts spending hard or defers investments. For a body whose core product is testing capacity, spending cuts can mean reduced investment in that very capacity. A clean paper surplus can mask a real-world slowdown — which is why I always read the financials before the communications. The report's final section describes a strategic pivot. WADA says it is moving from a model centered on traditional testing toward investigations and prevention. The specific figures: more than 250 investigation operations, 88 laboratories dismantled, and over 90 tons of substances seized. These are impressive and reflect a new direction, where the regulator does not merely wait for positives but actively hunts supply sources. Now it is worth stepping away from the conventional reading. The most common take on this report is: WADA expands testing, the system is getting healthier. That reading has its own logic — sample growth is real and the data is real. But it overlooks several blind spots. One blind spot is the gap between headline and data. A report saying WADA expands testing leads readers to picture a steadily rising curve. In reality the curve is flattening: up 12.5%, then 3.2%. If the trend continues, growth could approach zero within a few years — not because the system abandons testing, but because capacity has hit a resource ceiling. This is where the difference between having more samples than last year and actually accelerating becomes crucial. A higher absolute figure does not mean momentum is still strong. Another blind spot is the inverted direction of compliance metrics. When the aggregate improves while procedure-related findings rise, you face a system that looks better on paper and worse in operation. For swimming, the operational layer is out-of-competition sample collection — where a minor procedural lapse can strip an athlete's case of legal value. One athlete can be suspended for an administrative sampling error while another in a well-resourced country is handled correctly. This asymmetry is a fairness issue more than a technical one. The most notable blind spot is the financial model. The two largest countries falling behind raises a question the report does not answer: if resources tighten, which testing will WADA prioritize? A budget-constrained agency tends to favor investigations with clear results over broad routine testing. That sounds efficient, but it shifts part of the burden onto testing-intensive sports, swimming among them. Small swimming federations, with no voice in global budget allocation, are the most likely to be left behind. The pivot toward investigations and prevention also needs closer reading. More than 250 operations, 88 dismantled labs, 90 tons seized — impressive results, but they belong to a different domain than athlete testing. An investigation that dismantles a supply network does not automatically mean a swimmer in a small federation gets tested more often. These two capabilities are not substitutes, even when presented side by side in one release. Two milestone events remain. First, the athlete-centered consultation, with more than 600 athletes and commissions from over 60 countries and more than 70 sports. Second, the adoption of the 2027 World Anti-Doping Code in Busan, South Korea, effective January 1, 2027. On the consultation, the scale is real and worth noting. But the report offers no measure showing athletes' voices actually changed the Code's substance. Participation counts measure reach, not influence. That is a gap readers must fill by tracking specific texts over the next two years. A broad consultation can be a legitimate procedural step, but it only gains substance if concrete proposals make it into the final text. On the 2027 Code, this is the highest-action-value signal in the entire report. A fixed timeline now exists. From now to January 1, 2027 is a transition period, and within it sits a compliance trough: old rules operate, new rules are not yet in force, and organizations can delay adaptation. For swimming federations, this is the window to watch which countries update procedures early and which wait until the last minute. A few concrete signals belong on the watch list for the next two years. The testing-volume growth rate in the next report — if it stalls or turns negative, that signals capacity erosion. The AAF rate across 2026 and 2026 — if it breaks above roughly 0.85%, the prevalence assumption needs review. The testing-non-conformity share in compliance audits — if it keeps rising past 45%, the problem is systemic rather than individual. US and Russian contribution status — any change directly affects operational capacity. And finally, national readiness ahead of January 1, 2027. What I take from this report is not the headline number. It is that three independent pressures are converging: decelerating testing growth, rising procedural testing errors, and the two largest funders falling behind. Each is manageable alone. Together they erode exactly what an anti-doping system must protect most: the ability to guarantee uniform testing for every athlete, in every country, at every moment. For someone who covers swimming, the report's value is contextual and regulatory rather than competitive. It does not say which swimmer is rising or which stroke is changing. It describes the ground on which every record is set or doubted. The stretch from now to January 1, 2027 will be the test. If countries adapt early, the compliance trough narrows. If not, the new Code enters force atop an operational system still carrying unpatched gaps. And when a testing system lacks the resources to cover evenly, the ones who lose are always the clean athletes — the people who never make headlines, yet are the entire reason the machinery exists.